Cargando…

Phase I Trial of (99m)Tc-(HE)(3)-G3, a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer

Radionuclide molecular imaging of human epidermal growth factor receptor type 2 (HER2) expression may enable a noninvasive discrimination between HER2-positive and HER2-negative breast cancers for stratification of patients for HER2-targeted treatments. DARPin (designed ankyrin repeat proteins) G3 i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bragina, Olga, Chernov, Vladimir, Schulga, Alexey, Konovalova, Elena, Garbukov, Eugeniy, Vorobyeva, Anzhelika, Orlova, Anna, Tashireva, Liubov, Sörensen, Jens, Zelchan, Roman, Medvedeva, Anna, Deyev, Sergey, Tolmachev, Vladimir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Society of Nuclear Medicine 2022
Materias:	Clinical (Molecular Imaging: Peptides)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8973295/ https://www.ncbi.nlm.nih.gov/pubmed/34385343 http://dx.doi.org/10.2967/jnumed.121.262542

Ejemplares similares

Optimal composition and position of histidine-containing tags improves biodistribution of (99m)Tc-labeled DARPin G3
por: Vorobyeva, Anzhelika, et al.
Publicado: (2019)

Direct In Vivo Comparison of (99m)Tc-Labeled Scaffold Proteins, DARPin G3 and ADAPT6, for Visualization of HER2 Expression and Monitoring of Early Response for Trastuzumab Therapy
por: Tolmachev, Vladimir, et al.
Publicado: (2022)

Comparative Preclinical Evaluation of Peptide-Based Chelators for the Labeling of DARPin G3 with (99m)Tc for Radionuclide Imaging of HER2 Expression in Cancer
por: Larkina, Mariia, et al.
Publicado: (2022)

Indirect Radioiodination of DARPin G3 Using N-succinimidyl-Para-Iodobenzoate Improves the Contrast of HER2 Molecular Imaging
por: Vorobyeva, Anzhelika, et al.
Publicado: (2019)

Direct Intra-Patient Comparison of Scaffold Protein-Based Tracers, [(99m)Tc]Tc-ADAPT6 and [(99m)Tc]Tc-(HE)(3)-G3, for Imaging of HER2-Positive Breast Cancer
por: Bragina, Olga, et al.
Publicado: (2023)

Feasibility of Imaging EpCAM Expression in Ovarian Cancer Using Radiolabeled DARPin Ec1
por: Vorobyeva, Anzhelika, et al.
Publicado: (2020)

Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin–Toxin Fusion in a Pancreatic Cancer Xenograft Model
por: Xu, Tianqi, et al.
Publicado: (2023)

Radionuclide Molecular Imaging of EpCAM Expression in Triple-Negative Breast Cancer Using the Scaffold Protein DARPin Ec1
por: Vorobyeva, Anzhelika, et al.
Publicado: (2020)

Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors
por: Vorobyeva, Anzhelika, et al.
Publicado: (2018)

Phase I clinical evaluation of (99m)Tc-labeled Affibody molecule for imaging HER2 expression in breast cancer
por: Bragina, Olga, et al.
Publicado: (2023)

Visualization of epithelial cell adhesion molecule-expressing renal cell carcinoma xenografts using designed ankyrin repeat protein Ec1 labelled with (99m)Tc and (125)I
por: Tolmachev, Vladimir, et al.
Publicado: (2022)

Phase I Trial of [(99m)Tc]Tc-maSSS-PEG(2)-RM26, a Bombesin Analogue Antagonistic to Gastrin-Releasing Peptide Receptors (GRPRs), for SPECT Imaging of GRPR Expression in Malignant Tumors
por: Chernov, Vladimir, et al.
Publicado: (2023)

Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPin Ec1
por: Deyev, Sergey M., et al.
Publicado: (2021)

Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model
por: Xu, Tianqi, et al.
Publicado: (2021)

Comparison of tumor-targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2
por: Vorobyeva, Anzhelika, et al.
Publicado: (2019)

On the prevention of kidney uptake of radiolabeled DARPins
por: Altai, Mohamed, et al.
Publicado: (2020)

Phase I Clinical Trial Using [(99m)Tc]Tc-1-thio-D-glucose for Diagnosis of Lymphoma Patients
por: Chernov, Vladimir, et al.
Publicado: (2022)

Epithelial cell adhesion molecule-targeting designed ankyrin repeat protein-toxin fusion Ec1-LoPE exhibits potent cytotoxic action in prostate cancer cells
por: Xu, Tianqi, et al.
Publicado: (2022)

The GRPR Antagonist [(99m)Tc]Tc-maSSS-PEG(2)-RM26 towards Phase I Clinical Trial: Kit Preparation, Characterization and Toxicity
por: Abouzayed, Ayman, et al.
Publicado: (2023)

Preclinical Evaluation of (99m)Tc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake
por: Oroujeni, Maryam, et al.
Publicado: (2021)

Influence of composition of cysteine-containing peptide-based chelators on biodistribution of (99m)Tc-labeled anti-EGFR affibody molecules
por: Oroujeni, Maryam, et al.
Publicado: (2018)

Dual Targeting of Cancer Cells with DARPin-Based Toxins for Overcoming Tumor Escape
por: Shramova, Elena, et al.
Publicado: (2020)

Preclinical Evaluation of (99m)Tc-Labeled GRPR Antagonists maSSS/SES-PEG(2)-RM26 for Imaging of Prostate Cancer
por: Abouzayed, Ayman, et al.
Publicado: (2021)

Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m
por: Garousi, Javad, et al.
Publicado: (2017)

HER3 PET Imaging: (68)Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to (89)Zr-Labeled Antibody and Antibody-Fragment-Based Tracers
por: Rinne, Sara S., et al.
Publicado: (2021)

Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules
por: Rinne, Sara S., et al.
Publicado: (2020)

Radionuclides in Diagnostics and Therapy of Malignant Tumors: New Development
por: Tolmachev, Vladimir, et al.
Publicado: (2022)

Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody Molecule (188)Re-ZHER2:41071
por: Liu, Yongsheng, et al.
Publicado: (2022)

Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibody–DM1 Drug Conjugates
por: Ding, Haozhong, et al.
Publicado: (2019)

Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model
por: Xu, Tianqi, et al.
Publicado: (2020)

Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart
por: Garousi, Javad, et al.
Publicado: (2022)

Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs
por: Altai, Mohamed, et al.
Publicado: (2018)

DARPins: Promising Scaffolds for Theranostics
por: Shilova, O. N., et al.
Publicado: (2019)

Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of (68)Ga-Labeled Tracers
por: Dahlsson Leitao, Charles, et al.
Publicado: (2019)

Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution
por: Ding, Haozhong, et al.
Publicado: (2021)

Radionuclide Therapy of HER2-Expressing Xenografts Using [(177)Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab
por: Liu, Yongsheng, et al.
Publicado: (2023)

Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake
por: Rosestedt, Maria, et al.
Publicado: (2019)

The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer
por: Bragina, O. D., et al.
Publicado: (2022)

(99m)Tc-labeled nanocolloid drugs: development methods
por: Sadkin, Vladimir, et al.
Publicado: (2020)

Penetration Efficiency of Antitumor Agents in Ovarian Cancer Spheroids: The Case of Recombinant Targeted Toxin DARPin-LoPE and the Chemotherapy Drug, Doxorubicin
por: Sokolova, Evgeniya, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hpb3h7e0a96ervnk9pmf8j8f8i